Aisling Capital believes the next decade will be marked by a revolution in healthcare driven by new therapeutics generated by
Business Model:
Revenue: $15.1M
Employees: 2-10
Address: 888 7th Ave
City: New York
State: NY
Zip: 10106
Country: US
Aisling Capital believes the next decade will be marked by a revolution in healthcare driven by new therapeutics generated by biotechnology. The completion of the human genome has given scientists new insights into the causes of human disease. These insights, combined with the past 20 years of developments in the biotechnology industry, are leading to rapid expansion of novel approaches toward the diagnosis, prevention, and treatment of life-threatening illnesses. These advances have led to an ever-increasing demand for capital to complete the development and commercialization of new therapeutics. Our goal is to support the leading global healthcare companies that are building on these technical and medical breakthroughs to commercialize new healthcare products.
Contact Phone:
+12126516380
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
2/2015 | Cidara Therapeutics | Series B | 42M |
4/2018 | Eidos Therapeutics | Series B | 0 |
10/2007 | Paratek Pharmaceuticals | Post-IPO Equity | 40M |
4/2018 | Zosano Pharma | Post-IPO Equity | 50M |
8/2010 | ViewRay | Series C | 20M |
2/2012 | ADMA Biologics | Venture Round | 0 |
4/2014 | Earlens | Series B | 40M |
8/2012 | Intercept Pharmaceuticals | Series C | 30M |
9/2011 | ViewRay | Debt Financing | 10M |
11/2016 | Biohaven Pharmaceutical | Venture Round | 80M |
7/2007 | Xanodyne | Series A | 25M |
11/2017 | Arcus Biosciences | Series C | 107M |
4/2007 | Sirion Therapeutics | Series B | 45M |
12/2020 | Reneo Pharmaceuticals | Series B | 0 |
7/2021 | Wugen | Series B | 0 |
4/2007 | Natural Dentist | Series B | 13.2M |
3/2016 | Zavante Therapeutics | Series A | 45M |
1/2017 | Ajax Health | Series A | 95M |
6/2014 | Cidara Therapeutics | Series A | 32M |
7/2020 | Elevation Oncology | Series A | 32.5M |
9/2017 | BridgeBio Pharma | Series C | 135M |
7/2014 | Paratek Pharmaceuticals | Post-IPO Debt | 93M |
1/2012 | Roka Bioscience | Series D | 47.5M |
10/2013 | Versartis | Series D | 0 |
1/2002 | Allos Therapeutics | Private Equity Round | - |
6/2014 | PowerVision | Series D | 30M |
9/2008 | Bridge Pharmaceuticals | Series B | 53.3M |
5/2008 | Esperion | Series A | 22.8M |
6/2007 | BioRelix | Series A | 25.8M |
3/2012 | LENSAR, Inc. | Venture Round | 24M |
10/2013 | LENSAR, Inc. | Debt | 60M |
10/2013 | LENSAR, Inc. | Equity | 27M |
10/2013 | Loxo Oncology | Series A | 33M |
9/2018 | Atreca | Series C | 125M |
4/2015 | Spirox | Series B | 18.5M |
3/2016 | Spirox | Series C | 45M |
10/2009 | Xanodyne | Venture Round | 0 |
7/2007 | Cempra | Series B | 0 |
11/2012 | Ambit Biosciences | Venture Round | 0 |
7/2018 | Ajax Health | Series B | 120M |
4/2021 | Antios Therapeutics | Series B | 0 |
3/2017 | Promentis Pharmaceuticals | Series C | 26M |
7/2015 | ViewRay | Post-IPO Equity | 0 |
2/2015 | Agile Therapeutics | Post-IPO Equity | 0 |
6/2016 | Miramar Labs | Venture Round | - |
2/2023 | Garuda Therapeutics | Series B | 0 |
6/2010 | Zeltiq Aesthetics | Series D | 25M |
11/2020 | Elevation Oncology | Series B | 65M |
8/2011 | T2 Biosystems | Series D | 0 |
1/2021 | Biomea Fusion | Series A | 56M |
9/2017 | GTx | Post-IPO Equity | 48.5M |
6/2016 | Verona Pharma | Post-IPO Equity | 65.6M |
4/2010 | Aragon Pharmaceuticals, Inc. | Series B | 22M |
10/2018 | Earlens | Series D | 0 |
11/2015 | ObsEva | Series B | 60M |
10/2013 | Seragon Pharmaceuticals | Series A | 30M |
2/2018 | Avrobio | Series B | 60M |
2/2012 | CeNeRx BioPharma | Series D | 4.6M |
7/2020 | Verona Pharma | Private Placement | 200M |
4/2019 | Poseida Therapeutics | Series C | 0 |
3/2012 | Cytos | Post-IPO Equity | 40M |
10/2014 | Miramar Labs | Series D | 26M |
4/2007 | Bioenvision | Venture Round | 7.4M |
4/2004 | Cardiokine | Series A | 37M |
2/2020 | Spruce Biosciences | Series B | 88M |
3/2015 | Aimmune Therapeutics | Series B | 80M |
7/2017 | VYNE Therapeutics | Series C | 50.5M |
7/2012 | Agile Therapeutics | Series C | 0 |
4/2013 | Esperion | Venture Round | 33M |
9/2022 | Forge Biologics | Series C | 0 |
1/2016 | Syros Pharmaceuticals | Series C | 40M |
5/2013 | ViewRay | Venture Round | 15M |
11/2021 | Antios Therapeutics | Series B | 0 |
7/2013 | TRIA Beauty | Private Equity Round | 0 |
4/2019 | Ajax Health | Series C | 85M |
4/2016 | PowerVision | Series D | 10M |
3/2015 | Cynapsus Therapeutics | Venture Round | 16.6M |
7/2008 | TRIA Beauty | Series E | 30M |
6/2017 | Earlens | Series C | 0 |
10/2012 | Aragon Pharmaceuticals, Inc. | Series D | 50M |
2/2011 | TRIA Beauty | Venture Round | 26.3M |
10/2012 | TRIA Beauty | Venture Round | 7.5M |
9/2021 | Garuda Therapeutics | Series A | 72M |
10/2019 | Nuvation Bio | Series A | 275M |
1/2011 | NextWave Pharmaceuticals | Series C | 45M |
10/2002 | Oculex Pharmaceuticals | Series B | 50M |
1/2015 | LENSAR, Inc. | Private Equity Round | 16M |
1/2019 | BridgeBio Pharma | Equity | 299.2M |
6/2009 | Cempra | Series C | 46M |
6/2016 | Aclaris Therapeutics | Post-IPO Equity | 20M |
4/2006 | Cempra | Series A | 22M |
12/2016 | Prolacta Bioscience | Venture Round | 0 |
5/2002 | Advion Inc. | Series B | 15M |
3/2013 | T2 Biosystems | Series E | 40M |
10/2014 | Syros Pharmaceuticals | Series B | 53M |
8/2014 | Dermira | Series C | 51M |
9/2020 | Monte Rosa Therapeutics | Series B | 0 |
7/2013 | Versartis | Series C | 0 |
5/2014 | Loxo Oncology | Series B | 24M |
6/2016 | Earlens | Series C | 0 |
3/2021 | Monte Rosa Therapeutics | Series C | 0 |
1/2013 | Versartis | Series C | 0 |
10/2020 | Talaris Therapeutics | Series B | 0 |
2/2014 | Versartis | Series E | 55M |
4/2012 | PreCision Dermatology | Venture Round | 29.4M |
6/2016 | F2G | Series E | 60M |
6/2022 | Dren Bio | Series B | 0 |
1/2008 | ViewRay | Series B | 25M |
12/2013 | ViewRay | Venture Round | 0 |
3/2012 | ViewRay | Series C | 45M |
12/2007 | Topaz Pharmaceuticals Inc | Series A | 20M |
2/2011 | Pharmaron | Series C | 40M |
10/2009 | Asensus Surgical | Post-IPO Equity | 0 |
6/2019 | Ajax Health | Series C | 15M |
6/2022 | Dren Bio | Series B | 0 |
11/2021 | Antios Therapeutics | Series B | 0 |
9/2021 | Garuda Therapeutics | Series A | 0 |
7/2021 | Wugen | Series B | 0 |
4/2021 | Antios Therapeutics | Series B | 0 |
3/2021 | Monte Rosa Therapeutics | Series C | 0 |
1/2021 | Biomea Fusion | Series A | 0 |
12/2020 | Reneo Pharmaceuticals | Series B | 0 |
11/2020 | Elevation Oncology | Series B | 0 |
10/2020 | Talaris Therapeutics | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|